Business brief
Home Depot's Express Delivery, Paramount's Bond Motion, and VC Antitrust Probes
Home Depot leans on small repair delivery, Paramount demands a $1.88B litigation bond from state AGs, and the DOJ targets VC board seats.
Business
The DOJ's antitrust probe into Andreessen Horowitz signals federal enforcement of overlapping board seats is expanding beyond Big Tech into venture capital.
BackgroundSection 8 of the Clayton Act prohibits individuals or investment firms from serving on board positions at competing corporations. Federal regulators enforce the rule to prevent anti-competitive collusion and information sharing across shared markets.
- DOJ antitrust officials are focused on Ben Horowitz's board seat at Databricks while general partner Martin Casado serves on Fivetran's board.
- Both venture-backed startups operate in overlapping enterprise data processing and cloud AI infrastructure markets, raising potential antitrust conflict concerns.
- The probe follows antitrust review of Fivetran's acquisition of dbt Labs, which cleared federal scrutiny earlier this summer without structural remedies.
- Venture capital firms across Silicon Valley are auditing portfolio board assignments as federal enforcement of interlocking directorates tightens.
Business
Home Depot is rolling out fast delivery to protect revenues — proving home improvement demand is shifting to small repairs while housing turnover remains frozen.
BackgroundThe US housing market remains constrained by high mortgage rates, keeping home sales near multi-year lows. Home improvement retailers rely on small DIY repairs and contractor jobs when major home sales slow down.
- Q2 sales rose 5.7% year-over-year to $47.86 billion, driven by home maintenance demand as consumers shifted spending away from major renovations.
- Comparable store sales increased 1.7% globally and 1.3% in the US, topping consensus estimates and demonstrating steady underlying DIY repair activity.
- Management reaffirmed full-year sales growth guidance of 2.5% to 4.5%, signaling confidence that small repair projects can offset frozen housing turnover.
- Nationwide 3-hour flat-fee express delivery targets quick contractor job-site needs without requiring membership subscriptions, increasing pressure on rival hardware chains.
Business
Paramount's $1.88 billion bond demand weaponizes litigation costs against state regulators — trying to force prosecutors to risk public funds or abandon their antitrust suit.
BackgroundParamount and Warner Bros. Discovery agreed to combine in a $110 billion deal to compete against streaming giants Netflix and Apple. State prosecutors filed antitrust lawsuits claiming the consolidation harms consumers by raising subscription prices.
- Paramount incurs contractual ticking fees of roughly $7 million daily payable to Warner Bros. Discovery if closing stalls past September 30.
- With trial set for March 2027, Paramount told the court delay costs will exceed $1.3 billion in unrecoverable interest and operational penalties.
- California AG Rob Bonta called the bond motion an aggressive pressure tactic designed to intimidate state prosecutors from pursuing legitimate antitrust enforcement.
- A court decision on the bond motion is expected before September, setting a precedent for state antitrust litigation against corporate mega-mergers.
Business
LEO Pharma's $435 million deal expands its dermatological pipeline — securing an FDA-stage rare disease asset targeting sun-induced skin pain.
BackgroundErythropoietic protoporphyria is a rare genetic disorder causing severe skin pain upon exposure to sunlight. Specialty pharmaceutical firms expand into rare disease treatments to secure high-margin therapies with extended market exclusivity.
- The agreement includes upfront and near-term milestone payments totaling $435 million plus tiered commercial sales royalties on future global revenue.
- An NDA for once-daily oral dersimelagon was submitted to the US FDA in June 2026 following successful Phase 3 clinical trials.
- LEO Pharma simultaneously reported H1 2026 revenue of DKK 7.26 billion, driven by strong prescription sales growth across North America.
- Commercial launch is planned for 2027 pending FDA approval, establishing a core rare-disease growth driver for the Danish drugmaker.
Business
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
